title: [Development of novel agents for multiple myeloma; now and the future].
authors: Hiroyuki
authors: H
authors: Hata
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D000069461:Bendamustine Hydrochloride; D016227:Benzoquinones / Q000494:pharmacology / Q000627:therapeutic use; D001596:Benzylamines; D002986:Clinical Trials as Topic; D000080027:Cyclams; D055808:Drug Discovery / Q000639:trends*; D004359:Drug Therapy, Combination; D006571:Heterocyclic Compounds / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology / Q000627:therapeutic use; D047029:Lactams, Macrocyclic / Q000494:pharmacology / Q000627:therapeutic use; D058990:Molecular Targeted Therapy / Q000639:trends*; D009101:Multiple Myeloma / Q000188:drug therapy*; D009588:Nitrogen Mustard Compounds / Q000494:pharmacology / Q000627:therapeutic use; D009842:Oligopeptides / Q000494:pharmacology / Q000627:therapeutic use; D013792:Thalidomide / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000077337:Vorinostat
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D016227:Benzoquinones; D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D006877:Hydroxamic Acids; D047029:Lactams, Macrocyclic; D009588:Nitrogen Mustard Compounds; D009842:Oligopeptides; C546027:elotuzumab; C112765:tanespimycin; D013792:Thalidomide; D000077337:Vorinostat; C524865:carfilzomib; D000069461:Bendamustine Hydrochloride; C467566:pomalidomide; C088327:plerixafor